IMCY-0141

DB17019InvestigationalNucleic Acid Based Therapies

IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin sheath...

Mechanism: Pharmacologically active on Myelin-oligodendrocyte glycoprotein
Curator reviewed
Code names: IMCY-0141

Resolves to

Targets

Q16653MOG

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with IMCY-0141, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account